The strong efficacy and clean safety profile de-risk SPY002 as a potential best-in-class anti-TL1A. Watch for Part B randomized placebo-controlled data and SPY003 readout in Q3 2026, which could further validate the platform. The stock may re-rate upward on this catalyst, but given the open-label design and small sample (n=48), some skepticism may persist until confirmatory data.
Price Chart
Executive Summary
Spyre Therapeutics announced positive 12-week induction topline data from Part A of the Phase 2 SKYLINE trial of SPY002 (anti-TL1A) in moderate-to-severe ulcerative colitis. The primary endpoint was met with a statistically significant 10.7-point reduction in Robarts Histopathology Index (RHI) score (p<0.0001), with clinical remission of 33% and endoscopic improvement of 42%. Safety was consistent with the TL1A class with no drug-related serious adverse events. This de-risks SPY002 and supports the ongoing Part B randomized portion and combination arms.
Key Facts
- Primary endpoint met: 10.7-point reduction in RHI from baseline at Week 12 (p<0.0001)
- Clinical remission rate of 33% and endoscopic improvement rate of 42%
- Change in modified Mayo Score of -3.7
- Safety profile consistent with TL1A class; 2 SAEs deemed not drug-related, no drug-related SAEs, no deaths
- Study population: 35% advanced therapy-exposed, mean disease duration 7.0 years, 56% baseline endoscopy score of 3
- Company on track for SPY003 (anti-IL-23) Part A data in Q3 2026 and Part B enrollment underway
Financial Impact
No financial data in filing; positive clinical data likely increases probability of technical and regulatory success for SPY002, potentially enhancing partnership or valuation prospects for a $7B market cap biotech
Risk Factors
- Open-label Part A design with no placebo control limits comparative interpretation
- Small sample size (n=48) may not fully capture safety signals
- Competitive landscape includes other anti-TL1A programs (e.g., duvakitug from Teva/Sanofi) with Phase 2b data
- Part B randomized data expected later; failure to replicate would reverse gains
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001636282-26-000083 |
| Exhibit: exhibit99120260615skyline-.htm | 0001636282-26-000083 |
| Document: 0001636282-26-000083-index-headers.html | 0001636282-26-000083 |
| Document: 0001636282-26-000083-index.html | 0001636282-26-000083 |
| Document: 0001636282-26-000083.txt | 0001636282-26-000083 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | Insider Cluster | $88.98 $90.80 | ▼ −2.05% | ▼ −3.25% | $93.19 (−4.73%) |
Aug 11, 2026 7w ago | Insider Cluster | $102.74 $107.82 | ▼ −4.94% | ▼ −5.35% | $93.19 (+9.30%) |
Aug 6, 2026 8w ago | Insider Cluster | $103.42 $101.85 | ▲ +1.52% | ▲ +2.73% | $93.19 (+9.89%) |
Jul 3, 2026 13w ago | Insider Cluster | $86.63 $98.75 | ▲ +13.99% | ▲ +13.06% | $93.19 (+7.57%) |
Jun 27, 2026 13w ago | Insider Cluster | $90.16 $88.74 | ▲ +1.57% | ▲ +2.96% | $93.19 (−3.36%) |
Jun 26, 2026 14w ago | S-3ASR | $90.16 $88.74 | ▼ −1.57% | ▼ −2.96% | $93.19 (+3.36%) |
Jun 24, 2026 14w ago | Insider Cluster | $86.24 $88.89 | ▼ −3.07% | ▼ −1.37% | $93.19 (−8.06%) |
Jun 15, 2026 15w ago | 8-K | $83.58 $100.32 | ▲ +20.03% | ▲ +21.41% | $93.19 (+11.50%) |
Jun 12, 2026 16w ago | Institutional Cluster | $80.79 $88.34 | ▲ +9.35% | ▲ +8.67% | $93.19 (+15.35%) |
Jun 11, 2026 16w ago | Institutional Cluster | $80.77 $87.49 | ▲ +8.32% | ▲ +7.89% | $93.19 (+15.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access